BOT has to pay substantial royalities (license payments) to their licensor. They will look to make a one-off payment to the licensor in order to reduce these royalties. It will be cheaper (but riskier) to do it now, as there is no FDA approval / USA revenue. It ultimately means they can keep more of the income from sales.
BOT has to pay substantial royalities (license payments) to...
-
- There are more pages in this discussion • 186 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.010(3.17%) |
Mkt cap ! $588.2M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 33.5¢ | 30.5¢ | $4.678M | 14.78M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 84092 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 48995 | 2 |
View Market Depth
| Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |